Our Partnership
Key Structures
Topics
Results & Data
News Releases
-
02 February 2023
Global Fund Praises Luxembourg’s Additional Pledge, Bringing Total Contribution …
-
01 February 2023
African Leaders Unite in Pledge to End AIDS in Children
-
15 December 2022
Global Fund Welcomes Singapore’s Return As a Donor
-
14 December 2022
Global Fund and Private Sector Partners Launch US$50 Million Catalytic Fund to A…
Opinion
-
16 December 2022
The Criminalization of Sex Work Not Only Violates Human Rights – It Adds to HIV …
-
09 December 2022
A Hotline Operator’s Tireless Efforts to Keep People on Drug Treatment Despite W…
-
01 December 2022
The Best Way to Prepare for the Next Pandemic Is Not What You Think
-
30 November 2022
World AIDS Day: How are we supposed to protect our babies?
Updates
-
18 January 2023
2023-2025 Allocations Now Available
-
16 December 2022
Global Fund appoints Marijke Wijnroks as Head of Strategic Investment and Impact…
-
16 December 2022
TERG: Thematic Evaluation of the Global Fund’s Performance in Challenging Operat…
-
08 December 2022
Updated Resources for the Next Funding Cycle
Featured
Opportunity for Evaluation of Diagnostic Products
11 November 2019
The Global Fund and Unitaid are inviting manufacturers of diagnostic products to submit an Expression of Interest to have their products evaluated by the Expert Review Panel for Diagnostics (EPRD). This evaluation will focus particularly on diagnostic products addressing HIV Self testing. Detailed information about the review process and submission requirements can be found in the document below.
This is an open invitation and the submission of an Expression of Interest is possible at any time.
- Invitation to Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Diagnostics Products
download in English
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.